Martelli, V, Barrull, JV, Rodriguez, CF, Alfonso, PG, Paez, D, Gibert, J, Alonso, V, España, MAG, Vivas, CS, Ogalla, GD, Fernandez, MEE, Garcia-Carbonero, R, Monteagudo, RF, Mozo, JLM, Losa, F, Paricio, BB, Tabernero, J, Soler, RS, Aguilar, EA, Viladot, CM. Circulating tumor DNA (ctDNA) to detect acquired resistance to first-line (1L) treatment of RASWT metastatic colorectal cancer (mCRC): Insights from the PLATFORM-B study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/j.annonc.2024.05.121. PMID:. IF:65.400(Q1/1D).

Taieb, J, Fakih, M, Salvatore, L, Esaki, T, Modest, DP, Paez, D, Karamouzis, MV, Ruiz, E, Kim, TW, Kuboki, Y, Meriggi, FA, Cunningham, D, Yeh, KH, Cremolini, C, Wang, J, Tran, Q, Chao, J, Chen, Z, Pietrantonio, F. Patient-reported tolerability of sotorasib (soto) and panitumumab (pani) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in patients (pts) with metastatic colorectal cancer (mCRC) in the CodeBreaK 300 study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/j.annonc.2024.05.043. PMID:. IF:65.400(Q1/1D).

John, T, Grohe, C, Goldman, JW, Kato, T, Laktionov, KK, Bonanno, L, Tiseo, M, Majem, M, Domine, M, Ahn, MJ, Perol, M, Hartmaier, R, Robichaux, J, Bhetariya, P, Markovets, A, Rukazenkov, Y, Muldoon, C, Herbst, RS, Tsuboi, M, Wu, YL. Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

González-Lopez, JA, Sebio, A, Hindi, N, Jimenez, M, Villarejo-Campos, P, Martin-Broto, J, Díaz-Beveridge, R, Castellanos, JFO, Andújar, RL, Alvarez, RA, Asencio, JM, Serrano, C, Conde, NR, Boix, SC, Gimenez-Salinas, LK, Garcia, JAT, Campos, AP, Lopera, E, Bertran, J, Pousa, AL. First-in-human CEB-01: Novel loco-regional SN-38 release membrane to prevent local recurrence in retroperitoneal sarcomas. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).